Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

zirconium Zr 89-DFO-emapalumab

A radioimmunoconjugate comprised of emapalumab, a human monoclonal antibody directed against the cytokine interferon-gamma (IFN-gamma; IFNg), linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of Zr89-DFO-emapalumab, the emapalumab moiety specifically targets and binds to IFNg. Upon binding, the radioisotope moiety is detected using PET, thereby allowing the imaging of IFNg. This may help detect lesions and assess response to immunotherapeutic agents. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[89Zr]-DFO-emapalumab
zirconium Zr 89 DFO-emapalumab
Zr89-DFO-emapalumab
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search